Chinese cell therapy biotech developing TIL therapies raises $60M Series B
08 Sep 2023
Cell TherapyPhase 2Gene Therapy
Grit Biotechnology said Friday that it closed a Series B, raising more than $60 million from several Chinese investors.
The financing came from several new investors, including Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership, in addition to previous investors: Sherpa Healthcare Partners, Decheng Capital and Matrix Partners China.
Shanghai-based Grit said the funding would go toward developing its pipeline, including advancing its tumor-infiltrating lymphocyte (TIL) candidates and supporting a planned pivotal Phase II in China for its lead candidate, GT101. That therapy is currently being tested in melanoma and cervical and lung cancer.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.